B
Bioelectronica
A research-stage biotechnology company building next-generation digital tools for drug discovery, diagnostics, and cell sorting
About Bioelectronica
Bioelectronica is a research-stage biotechnology company focused on developing intelligent digital tools for drug discovery, cell screening, and cell sorting. Founded by Roger Chen and Jonathan Hull, the company leverages advanced technologies such as computer vision, biochemical reagents, and consumer electronics to accelerate the drug discovery process. Bioelectronica's flagship product, the Hypercell technology platform, offers high throughput digital biochemistry capabilities that enable quick and cost-effective analysis and sorting of cells, particularly secretors. This platform has been recognized for its innovation, notably being selected by the Society for Laboratory Automation and Screening as the most innovative new product in January 2020. Bioelectronica operates on a contract basis, providing cell sorting and analysis services to laboratories and research institutions. The company generates revenue through service contracts and sales of its proprietary technology. Bioelectronica serves clients in the life sciences sector, including pharmaceutical companies, academic institutions, and research labs, aiming to enhance their research capabilities and accelerate scientific discoveries. Keywords: digital biochemistry, cell sorting, drug discovery, computer vision, biochemical reagents, high throughput, life sciences, research-stage, biotechnology, Hypercell.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Reno, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 41.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Bioelectronica.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2021 | $16M | $64M | Cowin Venture · Proxima Ventures | — |
| SEEDEquity / VC | May 2019 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Bioelectronica is 1.7K monthly website visits, up 95.4% over the last three months. Bioelectronica's team declined 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Proxima Ventures
Cowin Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bioelectronica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bioelectronica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.